BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 28, Issue 20
  • This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (9341)
All Articles published online
The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.
Item 
Count 
PDF503
WORD76
HTML4601
Figures (1-2)714
Tables (1-2)665
 Sum=6559
Featured Article
The chart showing Browse series, Download series.
Item 
Count 
Browse298
Download758
 Sum=1056
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse436
Download1290
 Sum=1726
May 28, 2022 (publication date) through Oct 30, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews
Copyright ©The Author(s) 2022.
World J Gastroenterol. May 28, 2022; 28(20): 2163-2175
Published online May 28, 2022. doi: 10.3748/wjg.v28.i20.2163
Table 1 Ongoing clinical trials of immune checkpoint inhibitors in combination with other therapies for the treatment of neuroendocrine neoplasms
Drugs
Population
n
Phase
Primary outcomes
NCT number
Surufatinib + toripalimab vs FOLFIRINEC194IIIOSNCT05015621
Penpulimab + anlotinibNET150IIORRNCT04207463
Pembrolizumab + liver-directed/PRRTNET32ORRNCT03457948
Nivolumab + chemotherapyNEN G338IIOSNCT03980925
Toripalimab + FOLFSIM vs EP/ECAdvanced NEC336II/IIIOSNCT03992911
Nivolumab + ipilimumab + cabozantinibPD-NET30IIORRNCT04079712
Pembrolizumab + lanreotide depotGEP-NET22Ib/IIORRNCT03043664
FOLFIRI: Folinic acid, fluorouracil and irinotecan regimen; FOLFSIM: Simmtecan and 5-FU/LV regimen; EP: Etoposide and cisplatin regimen; EC: Etoposide and carboplatin regimen; PD-NET: Poorly differentiated neuroendocrine tumor; ORR: Objective response rate; OS: Overall survival.
Full Size Table
Table 2 Ongoing clinical trials of new targeted agents
Drugs
Targets
Population
n
Phase
Primary outcomes
NCT number
Ribociclib + EverolimusCDK4/6 InhibitorAdvanced NET21IIPFSNCT03070301
AbemaciclibCDK4/6 InhibitorAdvanced GEP-NET37IIORRNCT03891784
BAY 1895344ATR Kinase InhibitorSCLC/PD-NEC/PDA87IMTD, AEsNCT04514497
Lurbinectedin, berzosertibATR Kinase InhibitorSCLC/HGNEC75I/IIMTD, ORRNCT04802174
BI 764532DLL3 InhibitorSCLC/NEN Expressing DLL3110IMTDNCT04429087
EntinostatHDAC InhibitorAbdominal NET40IIORRNCT03211988
Niraparib + dostarlimabPARP InhibitorSCLC/HGNEC48PFS, ORRNCT04701307
SCLC: Small-cell lung carcinoma; PD-NEC: Poorly differentiated neuroendocrine carcinoma; PDA: Pancreatic adenocarcinoma; HGNEC: High-grade neuroendocrine cancer; CDK: Cyclin-dependent kinase; ATR kinase: Ataxia telangiectasia and RAD3-related kinase; DLL3: Delta-like protein 3; HDAC: Histone deacetylase; PARP: Poly (ADP-ribose) polymerase; PFS: Progression-free survival; MTD: Maximum tolerated dose; ORR: Objective response rate; AEs: Adverse events.
Full Size Table
Write to the Help Desk
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345